Constance T. Albarracin, M.D., Ph.D.

Peer-Reviewed Articles

1. Batra H, Bose PSC, Ding Y, Dai A, Chen H, Albarracin CT, Sun H, Sahin AA, Yang F, Wistuba II, Raso MG. MYB expression by immunohistochemistry is highly specific and sensitive for detection of solid variant of adenoid cystic carcinoma of the breast among all triple-negative breast cancers. Histopathology 85(3):503-509, 2024. e-Pub 2024. PMID: 38973399.
2. Sun H, Kang EY, Chen H, Sweeney KJ, Suchko M, Wu Y, Wen J, Krishnamurthy S, Albarracin CT, Ding QQ, Foo WC, Sahin AA. Immunohistochemical assessment of HER2 low breast cancer: interobserver reproducibility and correlation with digital image analysis. Breast Cancer Res Treat. e-Pub 2024. PMID: 38441847.
3. Wang J, Chen H, Koenig J, Wu Y, Bedrosian I, Arun B, Ding Q, Khazai L, Resetkova E, Huo L, Sneige N, Albarracin C. Discordance of Oncotype DX Scores in Synchronous Bilateral and Unilateral Multifocal Breast Cancers. Breast Cancer Res Treat 203(1):73-83, 2024. e-Pub 2023. PMID: 37751078.
4. Salem A, Wu Y, Albarracin CT, Middleton LP, Kalhor N, Peng Y, Huang X, Aung PP, Chen H, Sahin AA, Ding Q. A Comparative Evaluation of TRPS1 and GATA3 in adenoid cystic, secretory, and acinic cell carcinomas of the breast and salivary gland. Hum Pathol 145:42-47. e-Pub 2024. PMID: 38262580.
5. Zheng L, Luthra R, Alvarez HA, San Lucas FA, Duose DY, Wistuba II, Fuller GN, Ballester LY, Roy-Chowdhuri S, Sweeney KJ, Rashid A, Yang RK, Chen W, Liu A, Wu Y, Albarracin C, Patel KP, Routbort MJ, Sahin AA, Ding Q, Chen H. Intragenic EGFR::EGFR.E1E8 Fusion (EGFRvIII) in 4331 Solid Tumors. Cancers (Basel) 16(1), 2023. e-Pub 2023. PMID: 38201434.
6. Ye Q, Chen H, Han C, Peng Y, Huang X, Sun H, Wu Y, Albarracin CT, Middleton LP, Sahin AA, Huo L, Ding Q. Nuclear staining for pan-Trk by immunohistochemistry is highly specific for secretory carcinoma of breast: pan-Trk in various subtypes of breast carcinoma. J Clin Pathol. e-Pub 2023. PMID: 37586834.
7. Cho WC, Ding Q, Wang WL, Nagarajan P, Curry JL, Torres-Cabala CA, Ivan D, Albarracin CT, Sahin A, Prieto VG, Aung PP. Immunohistochemical Expression of TRPS1 in Mammary Paget Disease, Extramammary Paget Disease, and Their Close Histopathologic Mimics. J Cutan Pathol. e-Pub 2023. PMID: 36808637.
8. Wang M, Ding Q, Gu J, Sfamenos SM, Huo L, Tang Z, Sun H, Robinson M, Tang G, Lim B, Wu Y, Albarracin CT, Sahin AA, Chen H. Breast Cancer With a HER2 FISH Group 2 Result: Should HER2 Tests be Repeated?. Clin Breast Cancer. e-Pub 2023. PMID: 36878823.
9. Mistretta B, Rankothgedera S, Castillo M, Rao M, Holloway K, Bhardwaj A, El Noafal M, Albarracin C, El-Zein R, Rezaei H, Su X, Akbani R, Shao XM, Czerniecki BJ, Karchin R, Bedrosian I, Gunaratne PH. Chimeric RNAs Reveal Putative Neoantigen Peptides for Developing Tumor Vaccines for Breast Cancer. Front Immunol 14:1188831, 2023. e-Pub 2023. PMID: 37744342.
10. Yoon EC, Wang G, Parkinson B, Huo L, Peng Y, Wang J, Salisbury T, Wu Y, Chen H, Albarracin CT, Resetkova E, Middleton LP, Krishnamurthy S, Gan Q, Sun H, Huang X, Shen T, Chen W, Parwani AV, Sahin AA, Li Z, Ding Q. TRPS1, GATA3, and SOX10 expression in triple-negative breast carcinoma. Hum Pathol 125:97-107, 2022. e-Pub 2022. PMID: 35413381.
11. Zhou P, Chang N, Abraham SC, Albarracin CT, Huo L, Chen H, Ding Q, Resetkova E, Middleton LP, Sahin AA, Bu H, Wu Y. Metastatic non-Hematopoietic Neoplasms to the Breast: A Study of 238 Cases. Hum Pathol 125:59-67, 2022. e-Pub 2022. PMID: 35447141.
12. Wang J, Wang WL, Sun H, Huo L, Wu Y, Chen H, Gan Q, Meis JM, Maloney N, Lazar AJ, Yoon EC, Albarracin CT, Krishnamurthy S, Middleton LP, Resetkova E, Yu W, Tan D, Lu W, Solis Soto LM, Wang S, Wistuba II, Parwani AV, Prieto VG, Sahin AA, Li Z, Ding Q. Expression of TRPS1 in phyllodes tumor and sarcoma of the breast. Hum Pathol 121:73-80, 2022. e-Pub 2022. PMID: 35063444.
13. McLemore LE, Albarracin CT, Gruschkus SK, Bassett Jr. RL, Wu Y, Dhamne S, Yim I, Lin K, Bedrosian I, Sneige N, Chen H. HER2 Testing in Breast Cancers: Comparison of Assays and Interpretation Using ASCO/CAP 2013 and 2018 Guidelines. Breast Cancer Research and Treatment. e-Pub 2021. PMID: 33813685.
14. Kilgore LJ, Yi M, Bevers T, Coyne R, Lazzaro M, Lane D, Albarracin C, Bedrosian I. Risk of breast cancer in selected women with atypical ductal hyperplasia who do not undergo surgical excision. Ann Surg. e-Pub 2021. PMID: 33914469.
15. Yang L, Roy M, Lin H, Shen Y, Albarracin C, Huo L, Chen H, Wei B, Bedrosian I, Bu H, Wu Y. Validation of Prognostic Significance of the Proposed Uniform Classification Framework in Neuroendocrine Neoplasms of the Breast. Breast Cancer Res Treat. e-Pub 2021. PMID: 33528758.
16. Roy M, Teshome M, Damodaran S, Sahin AA, Khazai L, Arribas E, Candelaria RP, Scoggins ME, Lane DL, Giordano SH, Albarracin CT, Prieto VG, Nagarajan P. Male Mammary Paget Disease: A Tale of 2 Contrasting Cases. Am J Dermatopathol 42(12):981-985, 2020. PMID: 33289978.
17. Ai D, Yao J, Yang F, Huo L, Chen H, Lu W, Soto LMS, Jiang M, Raso MG, Wang S, Bell D, Liu J, Wang H, Tan D, Torres-Cabala C, Gan Q, Wu Y, Albarracin C, Hung MC, Meric-Bernstam F, Wistuba II, Prieto VG, Sahin AA, Ding Q. TRPS1: A highly sensitive and specific marker for breast carcinoma, especially for triple-negative breast cancer. Mod Pathol. e-Pub 2020. PMID: 33011748.
18. Karbasian N, Sohrabi S, Omofoye TS, Le-Petross H, Arun BK, Albarracin CT, Hess KR, Gutierrez-Barrera AM, Whitman GJ. Imaging Features of Triple Negative Breast Cancer and the Effect of BRCA Mutations. Curr Probl Diagn Radiol. e-Pub 2020. PMID: 32033821.
19. Asik E, Akpinar Y, Caner A, Kahraman N, Guray T, Volkan M, Albarracin C, Pataer A, Arun B, Ozpolat B. EF2-kinase targeted cobalt-ferrite siRNA-nanotherapy suppresses BRCA1-mutated breast cancer. Nanomedicine (Lond) 14(17):2315-2338, 2019. e-Pub 2019. PMID: 31432749.
20. Eghtedari M, Le-Petross H, Babiera GV, Albarracin CT, Hess KR, Woodtichartpreecha P, Whitman GJ. Not all patients with a diagnosis of a radial scar require excision. Breast J 25(4):792-794, 2019. e-Pub 2019. PMID: 31087426.
21. Tadros AB, Smith BD, Shen Y, Lin H, Krishnamurthy S, Lucci A, Barcenas CH, Hwang RF, Rauch G, Santiago L, Strom EA, DeSnyder SM, Yang WT, Black DM, Albarracin CT, Chavez-MacGregor M, Hunt KK, Kuerer HM. Ductal Carcinoma In Situ and Margins <2 mm: Contemporary Outcomes With Breast Conservation. Ann Surg 269(1):150-157, 2019. e-Pub 2017. PMID: 28742682.
22. Bhardwaj A, Singh H, Trinidad CM, Albarracin CT, Hunt KK, Bedrosian I. The isomiR-140-3p-regulated mevalonic acid pathway as a potential target for prevention of triple negative breast cancer. Breast Cancer Res 20(1):150, 2018. e-Pub 2018. PMID: 30537987.
23. Basho RK, Yam C, Gilcrease M, Murthy RK, Helgason T, Karp DD, Meric-Bernstam F, Hess KR, Valero V, Albarracin C, Litton JK, Chavez-MacGregor M, Hong D, Kurzrock R, Hortobagyi GN, Janku F, Moulder SL. Comparative Effectiveness of an mTOR-Based Systemic Therapy Regimen in Advanced, Metaplastic and Nonmetaplastic Triple-Negative Breast Cancer. Oncologist 23(11):1300-1309, 2018. e-Pub 2018. PMID: 30139837.
24. Clifton K, Gutierrez-Barrera A, Ma J, Bassett R, Litton J, Kuerer H, Moulder S, Albarracin C, Hortobagyi G, Arun B. Adjuvant versus neoadjuvant chemotherapy in triple-negative breast cancer patients with BRCA mutations. Breast Cancer Res Treat 170(1):101-109, 2018. e-Pub 2018. PMID: 29470805.
25. Akay CL, Albarracin C, Torstenson T, Bassett R, Mittendorf EA, Yi M, Kuerer HM, Babiera GV, Bedrosian I, Hunt KK, Hwang RF. Factors impacting the accuracy of intra-operative evaluation of sentinel lymph nodes in breast cancer. Breast J 24(1):28-34, 2018. e-Pub 2017. PMID: 28608612.
26. Basho RK, Gilcrease M, Murthy RK, Helgason T, Karp DD, Meric-Bernstam F, Hess KR, Herbrich SM, Valero V, Albarracin C, Litton JK, Chavez-MacGregor M, Ibrahim NK, Murray JL, Koenig KB, Hong D, Subbiah V, Kurzrock R, Janku F, Moulder SL. Targeting the PI3K/AKT/mTOR Pathway for the Treatment of Mesenchymal Triple-Negative Breast Cancer: Evidence From a Phase 1 Trial of mTOR Inhibition in Combination With Liposomal Doxorubicin and Bevacizumab. JAMA Oncol 3(4):509-515, 2017. e-Pub 2016. PMID: 27893038.
27. Raj SD, Sahani VG, Adrada BE, Scoggins ME, Albarracin CT, Woodtichartpreecha P, Posleman Monetto FE, Whitman GJ. Pseudoangiomatous Stromal Hyperplasia of the Breast: Multimodality Review With Pathologic Correlation. Curr Probl Diagn Radiol 46(2):130-135, 2017. e-Pub 2016. PMID: 26949063.
28. Chen H, Singh RR, Lu X, Huo L, Yao H, Aldape K, Abraham R, Virani S, Mehrotra M, Mishra BM, Bousamra A, Albarracin C, Wu Y, Roy-Chowdhuri S, Kanagal-Shamanna R, Routbort MJ, Medeiros LJ, Patel KP, Broaddus R, Sahin A, Luthra R. Genome-wide copy number aberrations and HER2 and FGFR1 alterations in primary breast cancer by molecular inversion probe microarray. Oncotarget 8(7):10845-10857, 2017. e-Pub 2017. PMID: 28125801.
29. Menen RS, Ganesan N, Bevers T, Ying J, Coyne R, Lane D, Albarracin C, Bedrosian I. Long-Term Safety of Observation in Selected Women Following Core Biopsy Diagnosis of Atypical Ductal Hyperplasia. Ann Surg Oncol 24(1):70-76, 2017. e-Pub 2016. PMID: 27573525.
30. Kuerer HM, Smith BD, Chavez-MacGregor M, Albarracin C, Barcenas CH, Santiago L, Edgerton ME, Rauch GM, Giordano SH, Sahin A, Krishnamurthy S, Woodward W, Tripathy D, Yang WT, Hunt KK. DCIS Margins and Breast Conservation: MD Anderson Cancer Center Multidisciplinary Practice Guidelines and Outcomes. J Cancer 8(14):2653-2662, 2017. e-Pub 2017. PMID: 28928852.
31. Sevcikova K, Zhuang Z, Garcia-Manero G, Alvarez RH, Kantarjian HM, Mego M, Albarracin C, Tang G, Strom SS, Medeiros LJ, Hortobagyi GN, Reuben JM, Khoury JD. Comprehensive Analysis of Factors Impacting Risks and Outcomes of Therapy-related Myeloid Neoplasms Following Breast Cancer Treatment. Leukemia 2015.122, 2016. e-Pub 2015. PMID: 25975189.
32. Sanford RA, Song J, Gutierrez-Barrera AM, Profato J, Woodson A, Litton JK, Bedrosian I, Albarracin CT, Valero V, Arun B. High Incidence of Germline BRCA Mutation in Patients with ER Low Positive/PR Low Positive/HER-2 Neu Negative Tumors. Cancer 121(19):3422-3427, 2015. e-Pub 2015. PMID: 26280679.
33. Miller T, Albarracin CT, Carkaci S, Whitman GJ, Adrada BE. Rare Malignant Tumors of the Breast. Journal Clinical Imaging Science 2015 5(58), 2015.
34. Peintinger F, Sinn B, Hatzis C, Albarracin C, Downs-Kelly E, Morkowski J, Gould R, Symmans WF. Reproducibility of Residual Cancer Burden for Prognostic Assessment of Breast Cancer After Neoadjuvant Chemotherapy. Mod Pathol 2015.53, 2015. e-Pub 2015. PMID: 25932963.
35. Song S, Honjo S, Jin J, Chang SS, Scott AW, Chen Q, Kalhor N, Correa AM, Hofstetter WL, Albarracin CT, Wu TT, Johnson RL, Hung MC, Ajani JA. The Hippo Coactivator YAP1 Mediates EGFR Overexpression and Confers Chemoresistance in Esophageal Cancer. Clin Cancer Res 14(2191):2580-90, 2015. e-Pub 2015. PMID: 25739674.
36. Bhardwaj A, Ganesan N, Tachibana K, Rajapakshe K, Albarracin CT, Gunaratne PH, Coarfa C, Bedrosian I. Annexin A1 Preferentially Predicts Poor Prognosis of Basal-like Breast Cancer Patients by Activating mTOR-S6 Signaling. PLoS One 10(5):e0127678, 2015. e-Pub 2015. PMID: 26000884.
37. Dawood S1, Haaland B, Albarracin C, Gupta S, Cortes J, Sim YY, Dent RA. Is the Proportion of Patients Diagnosed with Synchronous Stage IV Breast Cancer Who Survive More than Two Years Increasing over Time?. Oncology, 2015. e-Pub 2015.
38. Caruso JA, Karakas C, Zhang J, Yi M, Albarracin C, Sahin A, Bondy M, Liu J, Hunt KK, Keyomarsi K. Elafin is Downregulated During Breast and Ovarian Tumorigenesis but Its Residual Expression Predicts Recurrence. Breast Cancer Res 16(6):3417. e-Pub 2014. PMID: 25551582.
39. Elsayegh N, Kuerer HM, Lin H, Gutierrez Barrera AM, Jackson M, Muse KI, Litton JK, Albarracin C, Afrough A, Hortobagyi GN, Arun BK. Predictors That Influence Contralateral Prophylactic Mastectomy Election Among Women with Ductal Carcinoma In Situ Who Were Evaluated for BRCA Genetic Testing. Ann Surg Oncol 21(11):3466-72, 2014. e-Pub 2014. PMID: 24796968.
40. Xiang DB, Wei B, Abraham SC, Huo L, Albarracin CT, Zhang H, Babiera G, Caudle AS, Akay CL, Rao P, Zhao YJ, Lu X, Wu Y. Molecular Cytogenetic Characterization of Mammary Neuroendocrine Carcinoma. Hum Pathol 45(9):1951-6, 2014. e-Pub 2014. PMID: 25074542.
41. Albarracin CT, Sagar D.. Ki67 as a Biomarker of Prognosis and Prediction: Is it Ready for Use in Routine Pathology Practice? Current Breast Cancer Reports, 2014.
42. Bhardwaj A, Rosen D, Liu M, Liu Y, Hao Q, Ganesan N, Etzel CJ, Gullett A, Albarracin CT, Bedrosian I. Suppression of Akt-mTOR Pathway-A Novel Component of Oncogene Induced DNA Damage Response Barrier in Breast Tumorigenesis. PLoS One 9(5):e97076, 2014. e-Pub 2014. PMID: 24811059.
43. Wang J, Wei B, Albarracin CT, Hu J, Abraham SC, Wu Y. Invasive Neuroendocrine Carcinoma of The Breast: A Population-based Study From The Surveillance, Epidemiology and End Results (SEER) Database. BMC Cancer 14:147, 2014. e-Pub 2014. PMID: 24589259.
44. Krishnamurthy S, Mathews K, McClure S, Murray M, Gilcrease M, Albarracin C, Spinosa J, Chang B, Ho J, Holt J, Cohen A, Giri D, Garg K, Bassett RL, Liang K. Multi-institutional Comparison of Whole Slide Digital Imaging and Optical Microscopy for Interpretation of Hematoxylin-eosin-stained Breast Tissue Sections. Arch Pathol Lab Med 137(12):1733-9, 2013. e-Pub 2013. PMID: 23947655.
45. Li X, Deavers MT, Guo M, Liu P, Gong Y, Albarracin CT, Middleton LP, Huo L. The Effect of Prolonged Cold Ischemia Time on Estrogen Receptor Immunohistochemistry in Breast Cancer. Mod Pathol 26(1):71-8, 2013. e-Pub 2012. PMID: 22899286.
46. Li X, Lu Y, Liang K, Hsu JM, Albarracin C, Mills GB, Hung MC, Fan Z. Brk/PTK6 Sustains Activated EGFR Signaling Through Inhibiting EGFR Degradation and Transactivating EGFR. Oncogene 31(40):4372-83, 2012. PMID: 22231447.
47. Duan X, Sneige N, Gullett AE, Prieto VG, Resetkova E, Andino LM, Wu Y, Gilcrease MZ, Bedrosian I, Dawood S, Arun B, Albarracin CT. Invasive Paget Disease of the Breast: Clinicopathologic Study of an Underrecognized Entity in the Breast. Am J Surg Pathol 36(9):1353-8, 2012. PMID: 22895267.
48. Raghunathan A, Olar A, Vogel H, Parker JR, Coventry SC, Debski R, Albarracin CT, Aldape KD, Cahill DP, Powell SZ, Fuller GN. Isocitrate Dehydrogenase 1 R132H Mutation is Not Detected in Angiocentric Glioma. Ann Diagn Pathol 16(4):255-9, 2012. PMID: 22445362.
49. Olar A, Raghunathan A, Albarracin CT, Aldape KD, Cahill DP, Powell SZ, Goodman JC, Fuller GN. Absence of IDH1-R132H Mutation Predicts Rapid Progression of Non-enhancing Diffuse Glioma in Older Adults. Ann Diagn Pathol 16(3):161-70, 2012. PMID: 22197544.
50. Kuerer HM, Lari SA, Arun BK, Hu CY, Brewster A, Mittendorf EA, Albarracin CT, Babiera GV, Caudle AS, Wagner JL, Litton JK, Bedrosian I, Meric-Bernstam F, Lucci A, Hunt KK. Biologic Features and Prognosis of Ductal Carcinoma in Situ Are Not Adversely Impacted by Initial Large Body Mass. Breast Cancer Res Treat 133(3):1131-41, 2012. PMID: 22392043.
51. Geyer FC, Lacroix-Triki M, Colombo PE, Patani N, Gauthier A, Natrajan R, Lambros MB, Khalifeh I, Albarracin C, Orru S, Marchiò C, Sapino A, Mackay A, Weigelt B, Schmitt FC, Wesseling J, Sneige N, Reis-Filho JS. Molecular Evidence in Support of the Neoplastic and Precursor Nature of Microglandular Adenosis. Histopathology 60(6B):E115-30, 2012. PMID: 22486256.
52. Bayraktar S, Elsayegh N, Gutierrez Barrera AM, Lin H, Kuerer H, Tasbas T, Muse KI, Ready K, Litton J, Meric-Bernstam F, Hortobagyi GN, Albarracin CT, Arun B. Predictive factors for BRCA1/BRCA2 mutations in women with ductal carcinoma in situ. Cancer 118(6):1515-22, 2012. PMID: 22009639.
53. Albarracin CT, Sneige N, Gullett AE, Prieto VG, Resetkova E, Andino LM, Wu Y, Gilcrease MZ, Bedrosian I, Dawood S, Arun B, and Duan X. Clinicopathologic Features of Invasive Paget Disease of Breast: Experience from a Single Institution. International Academy of Pathology Cape Town, South Africa, 2012.
54. Bayraktar S, Gutierrez-Barrera AM, Liu D, Tasbas T, Akar U, Litton JK, Lin E, Albarracin CT, Meric-Bernstam F, Gonzalez-Angulo AM, Hortobagyi GN, Arun BK. Outcome of triple-negative breast cancer in patients with or without deleterious BRCA mutations. Breast Cancer Res Treat 130(1):145-53, 2011. PMID: 21830012.
55. Arun B, Bayraktar S, Liu DD, Gutierrez Barrera AM, Atchley D, Pusztai L, Litton JK, Valero V, Meric-Bernstam F, Hortobagyi GN, Albarracin C. Response to Neoadjuvant Systemic Therapy for Breast Cancer in BRCA Mutation Carriers and Non-carriers: A Single Institution Experience. J Clin Oncol 29(28):3739-46, 2011. PMID: 21900106.
56. Perry KD, Reynolds C, Rosen DG, Edgerton ME, Albarracin CT, Gilcrease MZ, Sahin AA, Abraham SC, Wu Y. Metastatic Neuroendocrine Tumors in the Breast: A Potential Mimic of In Situ and Invasive Mammary Carcinoma. Histopathology(59(4)):619-30, 2011.
57. Tian Z, Wei B, Tang F, Wei W, Gilcrease MZ, Huo L, Albarracin CT, Resetkova E, Middleton L, Sahin A, Xing Y, Hunt KK, Chen J, Bu H, Rashid A, Abraham SC, Wu Y. Prognostic Significance of Tumor Grading and Staging in Mammary Carcinomas With Neuroendocrine Differentiation. Hum Pathol 42(8):1169-77, 2011. PMID: 21334720.
58. Wu X, Chen F, Sahin A, Albarracin C, Pei Z, Zou X, Singh B, Xu R, Daniels G, Li Y, Wei J, Blake M, Schneider RJ, Cowin P, Lee P. Distinct function of androgen receptor coactivator ARA70alpha and ARA70beta in mammary gland development, and in breast cancer. Breast Cancer Res Treat 128(2):391-400, 2011. PMID: 20814820.
59. Moulder S, Moroney J, Helgason T, Wheler J, Booser D, Albarracin C, Morrow PK, Koenig K, Kurzrock R. Responses to Liposomal Doxorubicin, Bevacizumab, and Temsirolimus in Metaplastic Carcinoma of the Breast: Biologic Rationale and Implications for Stem-Cell Research in Breast Cancer. J Clin Oncol 29(19):e572-5, 2011. PMID: 21482991.
60. Tang F, Wei B, Tian Z, Gilcrease MZ, Huo L, Albarracin CT, Resetkova E, Zhang H, Sahin A, Chen J, Bu H, Abraham S, Wu Y. Invasive mammary carcinoma with neuroendocrine differentiation: histological features and diagnostic challenges. Histopathology 59(1):106-15, 2011. PMID: 21668471.
61. Resetkova E, Edelweiss M, Albarracin CT, Yang WT. Management of radial sclerosing lesions of the breast diagnosed using percutaneous vacuum-assisted core needle biopsy: recommendations for excision based on seven years' of experience at a single institution. Breast Cancer Res Treat 127(2):335-43, 2011. PMID: 18626769.
62. Shehu A, Albarracin C, Devi YS, Luther K, Halperin J, Le J, Mao J, Duan RW, Frasor J, Gibori G. The Stimulation of HSD17B7 Expression by Estradiol Provides a Powerful Feed-Forward Mechanism for Estradiol Biosynthesis in Breast Cancer Cells. Mol Endocrinol 25(5):754-66, 2011. PMID: 21372145.
63. Nguyen CV, Albarracin CT, Whitman GJ, Lopez A, Sneige N. Atypical Ductal Hyperplasia in Directional Vacuum-Assisted Biopsy of Breast Microcalcifications: Considerations for Surgical Excision. Ann Surg Oncol 18(3):752-61, 2011. PMID: 20972636.
64. Whitman GJ, Albarracin CT, Gonzalez-Angulo AM. Triple-Negative Breast Cancer: What the Radiologist Needs to Know. Semin Roentgenol 46(1):26-39, 2011. PMID: 21134526.
65. Resetkova E, Khazai L, Albarracin CT, Arribas E. Clinical and radiologic data and core needle biopsy findings should dictate management of cellular fibroepithelial tumors of the breast. Breast J 16(6):573-80, 2010. PMID: 21070433.
66. Liang K, Esteva FJ, Albarracin C, Stemke-Hale K, Lu Y, Bianchini G, Yang CY, Li Y, Li X, Chen CT, Mills GB, Hortobagyi GN, Mendelsohn J, Hung MC, Fan Z. Recombinant human erythropoietin antagonizes trastuzumab treatment of breast cancer cells via Jak2-mediated Src activation and PTEN inactivation. Cancer Cell 18(5):423-35, 2010. PMID: 21075308.
67. Dawood S, Gonzalez-Angulo AM, Albarracin C, Yu TK, Hortobagyi GN, Buchholz TA, Woodward WA. Prognostic factors of survival in the trastuzumab era among women with breast cancer and brain metastases who receive whole brain radiotherapy: a single-institution review. Cancer 116(13):3084-92, 2010. PMID: 20564633.
68. Gullett AE, Prieto VG, Lopez A, Klein K, Arun B, Bedrosian I, Resetkova E, Wu Y, Sneige N, Albarracin CT. Type of Mammary Paget Disease Is Associated With Disease Free Survival. United States and Canadian Academy of Pathology 2010 Annual Meeting Washington, DC, 2010.
69. Liedtke C, Broglio K, Moulder S, Hsu L, Kau SW, Symmans WF, Albarracin C, Meric-Bernstam F, Woodward W, Theriault RL, Kiesel L, Hortobagyi GN, Pusztai L, Gonzalez-Angulo AM. Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancer. Ann Oncol 20(12):1953-8, 2009. PMID: 19596702.
70. Maru DM, Singh RR, Hannah C, Albarracin CT, Li YX, Abraham R, Romans AM, Yao H, Luthra MG, Anandasabapathy S, Swisher SG, Hofstetter WL, Rashid A, Luthra R. MicroRNA-196a Is a Potential Marker of Progression during Barrett's Metaplasia-Dysplasia-Invasive Adenocarcinoma Sequence in Esophagus. Am J Pathol 174(5):1940-8, 2009. PMID: 19342367.
71. Dawood S, Broglio K, Esteva FJ, Yang W, Kau SW, Islam R, Albarracin C, Yu TK, Green M, Hortobagyi GN, Gonzalez-Angulo AM. Survival among women with triple-receptor-negative breast cancer and brain metastases. Ann Oncol 20(4):621-7, 2009. PMID: 19150943.
72. Downs-Kelly E, Nayeemuddin KM, Albarracin C, Wu Y, Hunt KK, Gilcrease MZ. Matrix-producing carcinoma of the breast: an aggressive subtype of metaplastic carcinoma. Am J Surg Pathol 33(4):534-41, 2009. PMID: 19047898.
73. Arun B, Vogel KJ, Lopez A, Hernandez M, Atchley D, Broglio KR, Amos CI, Meric-Bernstam F, Kuerer H, Hortobagyi GN, Albarracin CT. High Prevalence of Pre-invasive Lesions Adjacent to BRCA1/2-Associated Breast Cancers. Cancer Prev Res (Phila) 2(2):122-7, 2009. PMID: 19174581.
74. Dawood S, Broglio K, Kau SW, Green MC, Giordano SH, Meric-Bernstam F, Buchholz TA, Albarracin C, Yang WT, Hennessy BT, Hortobagyi GN, Gonzalez-Angulo AM. Triple receptor-negative breast cancer: the effect of race on response to primary systemic treatment and survival outcomes. J Clin Oncol 27(2):220-6, 2009. PMID: 19047281.
75. Kuerer HM, Albarracin CT, Yang WT, Cardiff RD, Brewster AM, Symmans WF, Hylton NM, Middleton LP, Krishnamurthy S, Perkins GH, Babiera G, Edgerton ME, Czerniecki BJ, Arun BK, Hortobagyi GN. Ductal carcinoma in situ: state of the science and roadmap to advance the field. J Clin Oncol 27(2):279-88, 2009. PMID: 19064970.
76. Luthra R, Singh RR, Luthra MG, Li YX, Hannah C, Romans AM, Barkoh BA, Chen SS, Ensor J, Maru DM, Broaddus RR, Rashid A, Albarracin CT. MicroRNA-196a targets Annexin A1: A microRNA-mediated mechanism of Annexin A1 downregulation in cancers. Oncogene 27(52):6667-78, 2008. PMID: 18663355.
77. Wei Y, Xia W, Zhang Z, Liu J, Wang H, Adsay NV, Albarracin C, Yu D, Abbruzzese JL, Mills GB, Bast RC, Hortobagyi GN, Hung MC. Loss of trimethylation at lysine 27 of histone H3 is a predictor of poor outcome in breast, ovarian and pancreatic cancers. Mol Carcinog 47(9):701-6, 2008. PMID: 18176935.
78. Atchley DP, Albarracin CT, Lopez A, Valero V, Amos CI, Gonzalez-Angulo AM, Hortobagyi GN, Arun BK. Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer. J Clin Oncol 26(26):4282-8, 2008. PMID: 18779615.
79. Khalifeh IM, Albarracin C, Diaz LK, Symmans FW, Edgerton ME, Hwang RF, Sneige N. Clinical, histopathologic, and immunohistochemical features of microglandular adenosis and transition into in situ and invasive carcinoma. Am J Surg Pathol 32(4):544-52, 2008. PMID: 18300793.
80. Ferreira M, Albarracin CT, Resetkova E. Pseudoangiomatous stromal hyperplasia tumor: A clinical, radiologic and pathologic study of 26 cases. Mod Pathol 21(2):201-7, 2008. PMID: 18084246.
81. Dawood S, Broglio K, Gonzalez-Angulo AM, Kau SW, Yang W, Albarracin C, Meric F, Hortobagyi G, Theriault R. Development of new cancers in patients with DCIS: The M.D. Anderson experience. Ann Surg Oncol 15(1):244-9, 2008. e-Pub 2007. PMID: 18043978.
82. Gokhale S, Rosen D, Sneige N, Diaz LK, Resetkova E, Sahin A, Liu J, Albarracin CT. Assessment of two automated imaging systems in evaluating estrogen receptor status in breast carcinoma. Appl Immunohistochem Mol Morphol 15(4):451-5, 2007. PMID: 18091390.
83. May SA, Deavers MT, Resetkova E, Johnson D, Albarracin CT. Giant cell tumor of soft tissue arising in breast. Ann Diagn Pathol 11(5):345-9, 2007. PMID: 17870021.
84. Wang KL, Wu TT, Choi IS, Wang H, Resetkova E, Correa AM, Hofstetter WL, Swisher SG, Ajani JA, Rashid A, Albarracin CT. Expression of epidermal growth factor receptor in esophageal and esophagogastric junction adenocarcinomas: association with poor outcome. Cancer 109(4):658-67, 2007. PMID: 17211865.
85. He J, Pan Y, Hu J, Albarracin C, Wu Y, Dai JL. Profile of ets gene expression in human breast carcinoma. Cancer Biol Ther 6(1):76-82, 2007. PMID: 17172821.
86. Huo L, Sneige N, Hunt KK, Albarracin CT, Lopez A, Resetkova E. Predictors of invasion in patients with core-needle biopsy-diagnosed ductal carcinoma in situ and recommendations for a selective approach to sentinel lymph node biopsy in ductal carcinoma in situ. Cancer 107(8):1760-8, 2006. PMID: 16977650.
87. Wang KL, Wu TT, Resetkova E, Wang H, Correa AM, Hofstetter WL, Swisher SG, Ajani JA, Rashid A, Hamilton SR, Albarracin CT. Expression of Annexin A1 in esophageal and esophagogastric junction adenocarcinomas: association with poor outcome. Clin Cancer Res 12(15):4598-604, 2006. PMID: 16899607.
88. Anderson P, Albarracin CT, Resetkova E. A large, fungating breast mass. Secretory carcinoma with apocrine differentiation. Arch Pathol Lab Med 130(4):e50-2, 2006. PMID: 16594759.
89. Chang KH, Albarracin C, Luthra R, Wang L, Zheng W, Malpica A, Deavers MT, Silva EG, Liu J. Discordant genetic changes in ovarian and endometrial endometrioid carcinomas: A potential pitfall in molecular diagnosis. Int J Gynecol Cancer 16(1):178-82, 2006. PMID: 16445630.
90. Edelweiss M, Rosen DG, Garcia MKP, Wu Y, Liu J, Albarracin CT. Estrogen and androgen receptors espression in primary breast carcinoma, axillary lymph nodes metastasis and distant metastasis. Annual Meeting of Endocrine Society Boston, MA, 2006.
91. Resetkova E, Albarracin C, Sneige N. Collagenous spherulosis of breast: morphologic study of 59 cases and review of the literature. Am J Surg Pathol 30(1):20-7, 2006. PMID: 16330938.
92. Symmans WF, Fiterman DJ, Anderson SK, Ayers M, Rouzier R, Dunmire V, Stec J, Valero V, Sneige N, Albarracin C, Wu Y, Ross JS, Wagner P, Theriault RL, Arun B, Kuerer H, Hess KR, Zhang W, Hortobagyi GN, Pusztai L. A single-gene biomarker identifies breast cancers associated with immature cell type and short duration of prior breastfeeding. Endocr Relat Cancer 12(4):1059-69, 2005. PMID: 16322343.
93. Resetkova E, Padula A, Albarraccin CT, Sneige N. Pathologic quiz case: a large, ill-defined cystic breast mass. Arch Pathol Lab Med 129:e79-80, 2005. PMID: 15737055.
94. Albarracin CT, Silva EG, Malpica A, Luthra R, Liu J. The role of hMSH3 and hMSH6 in ovarian endometrioid carcinoma and relationship with microsatellite instability phenotype. Oncol Rep 12(6):1217-9, 2004. PMID: 15547740.
95. Wang B, Rouzier R, Albarracin CT, Sahin A, Wagner P, Yang Y, Smith TL, Meric-Bernstam F, Marcelo AC, Hortobagyi GN, Pusztai L. Expression of sigma 1 receptor in human breast cancer. Breast Cancer Res Treat 87(3):205-14, 2004. PMID: 15528963.
96. Cai KQ, Albarracin C, Rosen D, Zhong R, Zheng W, Luthra R, Broaddus R, Liu J. Microsatellite instability and alteration of the expression of hMLH1 and hMSH2 in ovarian clear cell carcinoma. Hum Pathol 35(5):552-9, 2004. PMID: 15138928.
97. Liu J, Albarracin CT, Chang KH, Thompson-Lanza JA, Zheng W, Gershenson DM, Broaddus R, Luthra R. Microsatellite instability and expression of hMLH1 and hMSH2 proteins in ovarian endometrioid cancer. Mod Pathol 17(1):75-80, 2004. PMID: 14631366.
98. Albarracin CT, Jafri J, Montag AG, Hart J, Kuan SF. Differential expression of MUC2 and MUC5AC mucin genes in primary ovarian and metastatic colonic carcinoma. Hum Pathol 31(6):672-7, 2000. PMID: 10872659.
99. Albarracin CT, Frosch MP, Chin WW. The gonadotropin-releasing hormone receptor gene promoter directs pituitary-specific oncogene expression in transgenic mice. Endocrinology 140(5):2415-21, 1999. PMID: 10218996.
100. Telleria CM, Parmer TG, Zhong L, Clarke DL, Albarracin CT, Duan WR, Linzer DI, Gibori G. The different forms of the prolactin receptor in the rat corpus luteum: developmental expression and hormonal regulation in pregnancy. Endocrinology 138(11):4812-20, 1997. PMID: 9348210.
101. Duan WR, Parmer TG, Albarracin CT, Zhong L, Gibori G. PRAP, a prolactin receptor associated protein: its gene expression and regulation in the corpus luteum. Endocrinology 138(8):3216-21, 1997. PMID: 9231770.
102. Fernández-Vázquez G, Kaiser UB, Albarracin CT, Chin WW. Transcriptional activation of the gonadotropin-releasing hormone receptor gene by activin A. Mol Endocrinol 10(4):356-66, 1996. PMID: 8721981.
103. Gibori G, Albarracin C, Mao J, Duan WR, Zhong L, Champakasseril C, Parmer TG. PRL mediated regulation of protein phosphorylation and gene expression in the corpus luteum. Frontiers in Endocrinology 18:123-30, 1995.
104. Albarracin CT, Kaiser UB, Chin WW. Isolation and characterization of the 5'-flanking region of the mouse gonadotropin-releasing hormone receptor gene. . Endocrinology 135(6):2297-99, 1994. PMID: 7988412.
105. Albarracin CT, Parmer TG, Duan WR, Nelson SE, Gibori G. Identification of a major prolactin-regulated protein as 20 alpha-hydroxysteroid dehydrogenase: coordinate regulation of its activity, protein content, and messenger ribonucleic acid expression. Endocrinology 134(6):2453-60, 1994. PMID: 8194472.
106. Mao J, Duan WR, Albarracin CT, Parmer TG, Gibori G. Isolation and characterization of a rat luteal cDNA encoding 20 alpha-hydroxysteroid dehydrogenase. Biochem Biophys Res Commun 201(3):1289-95, 1994. PMID: 8024573.
107. Albarracin CT, Palfrey HC, Duan WR, Rao MC, Gibori G. Prolactin regulation of the calmodulin-dependent protein kinase III elongation factor-2 system in the rat corpus luteum. J Biol Chem 269(10):7772-6, 1994. PMID: 8126003.
108. Parmer TG, McLean MP, Duan WR, Nelson SE, Albarracin CT, Khan I, Gibori G. Hormonal and Immunological Characterization of The 32 Kilodalton Ovarian-Specific Protein. Endocrinology 131(5):2213-21, 1992. PMID: 1425419.
109. Albarracin CT, Gibori G. Prolactin Action on Luteal Protein Expression in The Corpus Luteum. Endocrinology 129(4):1821-30, 1991. PMID: 1833177.

Invited Articles

1. Albarracin CT, Balderwijns M, Lester SC. Paget Disease of the Breast. WHO Classification of Tumors: Breast Tumors; Tumors of the Nipple 5th:184, 2019.

Abstracts

1. Goets L, Ye Q, Sneige N, Wu Y, Bedrosian I, Chen H, Albarracin C. Histologic Review of Phyllodes Tumors: A Comparative Review with Patient Outcomes. Mod Pathol 104(3):S164-65, 2024.
2. Sun H, Huo L, Sweeney K, Resetkova E, Chai D, Chen H, |Albarracin C, Wu Y. SMARCA4/BRG1 Deficiency in Breast Carcinoma by Immunohistochemistry Study. Mod Pathol 104(3):S274-75, 2024.
3. Ye Q, Klippel D, Albarracin C, Chen H, Contreras A, Ding QQ, Huo L, Khazai L, Middelton L, Resetkova E, Sahin A, Sun H, Sweeney K, Symmans W, Wu Y, Krishnamurthy S. A Prospective Study of Real Time Whole Slide Imaging of Frozen Sections for Intraoperative Evaluation of Axillary Sentinel Lymph Nodes in Breast Cancer. Mod Pathol 104(3):S321-22, 2024.
4. Salem A, Han C, Wu Y, Albarracin C, Middleton L, Chen H, Sahin A, Ding QQ. A Comparative Evaluation of TRPS1 and GATA3 in Adenoid Cystic, Acinic Cell, and Secretory Carcinomas of the Breast and Salivary Glands. Mod Pathol 103(3):S206-7, 2023.
5. Chen H, Wu Y, Ding QQ, Huo L, Khazai L, Sahin A, Albarrcin C. HER2-low Breast Cancers: Comparison of HER2 Scores by Immunohistochemistry and Oncotype DX. Mod Pathol 103(3):114, 2023.
6. Kang EY, Chen H, Sweeney K, Suchko M, Wu Y, Wen J, Krishnamurthy S, Albarracin C, Ding QQ, Foo WC, Sahin A. Immunohistochemical Assessment of HER2-Low Breast Cancer: Interobserver Reproducibility and Correlation with Digital Image Analysis. Mod Pathol 103(3):1720, 2023. e-Pub 2023.
7. Ye Q, Liu A, Estrella J, Kalhor N, Albarracin C, Ding QQ, Wu Y. TRPS1 Expression in Neuroendocrine Neoplasms of Breast and Other Organs. Mod Pathol 103(3):237, 2023.
8. Wang M, Ding Q, Gu J, Sfamenos SM, Huo L, Tang Z, Sun H, Robinson M, Tang G, Lim B, Wu Y, Albarracin CTb, Sahin A, Chen H. Breast Cancer with a HER2 FISH Group 2 Result: Should HER2 Tests be Repeated?. Clin Breast Cancer, 2023. PMID: 26878823.
9. Wu Y, Mersereau M, Chen H, Albarracin CT. KI67 Quantitation in Breast cancer: A Comparative Analysis of Four Counting Methods, 2023.
10. Alireza Salem, Hui Chen, Constance T. Albarracin, Yun Wu, Nour Sneige, Laila Khazai,Qingqing Ding, Zhenya Tang, Aysegul Sahin, Esther C Yoon,. Correlation amongst Immunohistochemical (IHC) Scores, Fluorescence In Situ Hybridization (FISH) Groups and Final HER2 Status on Breast carcinoma (BC) and Quality Issues Surrounding Indeterminate FISH Tests: A Single Center Experience. United States & Canadian Academy of Pathology’s 111th Annual Meeting, 2022.
11. Prih Rohra, Constance Albarracin. Mammary Adenomyoepithelioma and Malignant Adenomyoepithelioma: Clinical, Histologic and Immunophenotypic Characteristics of 34 cases. United States & Canadian Academy of Pathology’s 111th Annual Meeting, 2022.
12. Keith Sweeney, Jing Wang, Constance T. Albarracin, Sinchita Roy-Chowdhuri, Keyur P. Patel, Mark Routbort, Qingqing Ding, Yun Wu, Lei Huo, Rajyalakshmi Luthra, Hui Chen. PTEN Alterations in Advanced ER+ Breast Cancer: Correlation with Clinicopathologic and Molecular Features. United States & Canadian Academy of Pathology’s 111th Annual Meeting, 2022.
13. Prih Rohra, Constance Albarracin. TRPS1 Expression is Frequently Seen in Mammary and Extramammary Paget Diseases, Except for Those Arising in the Perianal Skin. United States & Canadian Academy of Pathology’s 111th Annual Meeting, 2022.
14. Chen, H. Hou, T. Y. Huo, L. Wu, Y. Wang, W. L. B. Albarracin, C.. Significance of ER-/PR plus Breast Cancer Cases: Re-evaluation of Biomarker Status and Clinical Correlates. Laboratory Investigation 100(Suppl 1):1848-1848, 2020.
15. Yang, L. B. Roy, M. Albarracin, C. Huo, L. Bedrosian, I. Bu, H. Wu, Y.. Neuroendocrine Neoplasms (NENs) of the Breast Have Poorer Prognosis than Invasive Carcinoma of No Special Type (NST). Modern Pathology 33(Suppl 2):289-290, 2020.
16. Wang, J. Chen, H. Koenig, J. Bedrosian, I. Wu, Y. Albarracin, C.. Discordance of Oncotype DX Scores in Bilateral and Unilateral Multifocal Breast Cancers. Laboratory Investigation 100(Suppl 1):279-280, 2020.
17. Ai D, Yao J, Yang F, Huo L, Chen H, Lu W, Soto LMS, Jiang M, Raso MG, Wang SF, Bell D, Liu JS, Wang HW, Tan DF, Torres-Cabala C, Gan Q, Wu Y, Albarracin CT, Hung MC, Meric-Bernstam F, Wistube II, Prieto VG, Sahin AA, Ding QQ. TRPS1: a highly sensitive and specific marker for breast carcinoma, especially for triple-negative breast cancer. Modern Pathology, 2020.
18. Kilgore LJ, Yi M, Bevers TB, Coyne R, Lazzaro M, Lane DL, Albarracin CT, Bedrosian I. Breast cancer events in women with atypical ductal hyperplasia who do not undergo surgical excision. Journal of Clinical Oncology 38(15), 2020.
19. Arun B, Barrera AG, Layman RM, Gruschkus SK, Bedrosian I, Albarracin CT, Barcenas CH, Valero V, Litton JK, Tripathy D. Outcome of patients with breast cancer and a germline BRCA mutation in a prospective cohort. Journal of Clinical Oncology 38(15), 2020.
20. Chen H, Hou TY, Huo L, Wu Y, Wang WLB, Albarracin CT. Significance of ER-/PR plus Breast Cancer Cases: Re-evaluation of Biomarker Status and Clinical Correlates. Laboratory Investigation 100(Suppl 1):1848-1848, 2020.
21. Militello L, Barrera AMG, Kuerer H, Albarracin CT, Arun BK. Characteristics of ductal carcinoma in situ (DCIS) in patients who underwent multigene panel testing for hereditary breast cancer. Cancer Research 80(4), 2020.
22. Militello L, Barera AMG, Albarracin CT, Bedrosian I, Arun BK. Clinical characteristics of breast cancer patients with ATM mutations. Cancer Research 80(4), 2020.
23. Albarracin C, Trinidd CM, Song J, Ward K, Dhamne S, Rosen D, Wu Y, Chen H, Baghaki HS, Barrera AMG, Arun B.. Androgen Receptor Expression In BRCA-Associated Breast Cancers. Modern Pathology 31(Suppl 1):44-44, 2018.
24. Dhamne S, Arun B, Ward K, Wu Y, Rosen DG, Cui X, Resetkova E, Duan X, Chen H, Bedrosian I, Gutierrez Barrera A, Albarracin CT. BRCA1 and BRCA2 Associated Breast Cancers Demonstrate Distinct Histopathologic Features, Biomarker Expression Patterns and Molecular Subtypes. Modern Pathology 29:39a-39a, 2016.
25. Raj SD, Sahani VG, Adrada BE, Scoggins ME, Albarracin CT, Woodtichartpreecha P, Posleman Monetto FE, Whitman GJ. Pseudoangiomatous Stromal Hyperplasia of the Breast: Multimodality Review with Pathologic Correlation. Current Problems in Diagnostic Radiology, 2016.
26. Basho BK, Gilcrease M, Murthy R, Helgason T, Booser D, Karp D, Meric-Bernstam F, Hess K, Herbrich S, Valero V, Albarracin C, Litton JK, Chavez-MacGregor M, Ibrahim N, Murray J, Koenig K, Hong D, Subbiah V, Kurzrock R, Janku F, Moulder S. Targeting the PI3K/AKT/mTOR Pathway for the Treatment of Mesenchymal Triple-negative Breast Cancer: Evidence From a Phase 1 Trial of mTOR inhibition in Combination With Liposomal Doxorubicin and Bevacizumab. JAMA Oncol 3(4), 2015.
27. Dhamne S, Albarracin C. High Nuclear Expression of p27 Correlates with Luminal A Molecular Subtype of Ductal Carcinoma In Situ of Breast. United States and Canadian Academy of Pathology 2014 Annual Meeting Vancouver, BC, Canada, 2014, 2014.
28. Carkaci S, Adrada B, Geiser W, Albarracin C, Whitman G.. Specimen Radiography: How we Do It. Radiological Society of North America, 2013.
29. Barina A, Arun B, Sneige N, Gutierrez-Barrers AM, Rosen D, Abrahams S, Resetkova E, Wu Y, Albarracin CT.. Histology of Breast Cancer in Patients with Lynch Syndrome. United States and Canadian Academy of Pathology 2013 Annual Meeting Baltimore, MD, 2013.
30. Dawood SS, Haaland B, Albarracin CT, Gonzalez-Angulo AM, Gupta S, Cortes J, Yap YS, Yap YS.. Is The Proportion of Patients With Synchronous Stage IV Breast Cancer Surviving > 2 Years Increasing Over Time?, 2013.
31. Raj SD, Adrada B, Scoggins ME, Albarracin C, Posleman Monetto F, Whitman GJ.. Pseudoangiomatous Stromal Hyperplasia of the Breast (PASH): Multimodality Review with Pathologic Correlation. Radiological Society of North America, 2013.
32. Dawood SS, Lei X, Albarracin CT, Dent R, Gupta S, Cortes J, Mittendorf EA, Buchholz TA, Gonzalez-Angulo AM.. Incidence and Characteristics of Breast Cancer Following a Diagnosis of Ductal Carcinoma in Situ. American Society of Clinical Oncology, 2013.
33. Liang Y, Huo L, Albarracin C, Gong Y, Wu Y. Prognostic Significance of Multifocal Lesion in ER+ Breast Cancers. Radiological Society of North America, 2013.
34. Li X, Deavers MT, Guo M, Liu P, Gong Y, Albarracin CT, Middleton LP, Huo L.. The Effect of Prolonged Cold Ischemia Time on Estrogen Receptor Immunohistochemistry in Breast Cancer. Mod Pathol(26(1)):71-8, 2013. e-Pub 2012.
35. Gullett AE, Sneige N, Prieto VG, Kelly CM, Bassett RL, Resetkova E, Duan X, Li Y, Rosen D, Wu Y, Huo L, Klein K, Bedrosian I, Arun B, Hunt K, Albarracin CT. Pathological and Clinical Characteristics of Mammary Paget Disease: 25-Year Experience from a Major Tertiary Referral Center. United States and Canadian Academy of Pathology 2012 Annual Meeting Vancouver, BC, Canada, 2012.
36. Schneider M, Albarracin C, Arun B, Gutierrez Barrera AM, Bassett R, Dawood S, Saab D, Gao L, Bedrosian I, Rosen D. Association of p27kip1 expression and BRCA status among women with breast cancer: A single institution study. United States and Canadian Academy of Pathology 2012 Annual Meeting Vancouver, BC, Canada, 2012.
37. Zhu X, Chen J, Xing Y, Albarracin CT, Zhao Y, Rao P, Li X, Bell D,El-Naggar A, Abraham S, Wu Y. Adenoid Cystic Carcinoma of the Breast: Clinicopathologic and Molecular Analysis of 56 Cases. United States and Canadian Academy of Pathology 2012 Annual Meeting Vancouver, BC, Canada, 2012.
38. Dawood S, Gonzalez-Angulo AM, Liu S, Li Y, Albarracin CT.. Annexin expression and survival outcomes in women with breast cancer. Annual Meeting of the San Antonio Breast Society, 2012.
39. Albarracin CT. Association of p27kip1 Expression and BRCA Status Among Women With Breast Cancer: A Single Institution Study, 2011.
40. Duan X, Sneige N, Gullett AE, Prieto VG, Resetkova E, Albarracin CT. Minimally Invasive Paget Disease of Breast: An Under-Recognized Entity in the Breast. United States and Canadian Academy of Pathology 2011 Annual Meeting San Antonio, TX, 2011.
41. Raghunathan A, Olar A, Vogel H, Parker JR, Coventry SC, Debski R, Albarracin CT, Aldape KD, Cahill DP, Powell SZ, Fuller GN. Isocitrate Dehydrogenase 1 (IDH1) R132H Mutation Is Not Detected in Angiocentric Glioma. United States and Canadian Academy of Pathology 2011 Annual Meeting San Antonio, TX, 2011.
42. Olar A, Raghunathan A, Albarracin CT, Aldape KD, Cahill DP, Powell SZ, Goodman CJ, Fuller GN.. Absence of IDH1 R132H Mutation Predicts Rapid Progression of Non-enhancing Diffuse Glioma in Older Adults. United States and Candian Academy of Pathology 2011 Annual Meeting San Antonion, TX, 2011.
43. Wei B, Tian Z, Tang F, Wei W, Gilcrease MZ, Huo L, Albarracin CT, Resetkova E, Middleton LP, Sahin A, Chen J, Abraham SC, Wu Y. Prognostic Factors of Primary Invasive Mammary Neuroendocrine Carcinoma: Clinicopathologic Analysis of 74 Cases. United States and Canadian Academy of Pathology, 2010 Annual Meeting Washington, DC, 2010.
44. Gullett AE, Duan X, Fuller GN, Brown R, Li Y, Luthra R, Wiseman W, Resetkova E, Yao H, Puduvalli V, Wu Y, Bruner JM, Albarracin CT. Expression of Annexin A1 and Constitutive Activation of the Akt/m TOR Pathway in High-Grade Diffuse Gliomas: A Potential Connection with S Phase Kinase-Associated Protein(Skp2) in Glioma Progression. United States and Canadian Academy of Pathology Annual Meeting Boston, MA, 2009.
45. Chen S, Albarracin C, Wang H, Klein K, Sahin A, Wang H. Downregulation of Hematopoietic Progenitor Kinase 1 Protein Level in Ductal Carcinoma In Situ and Invasive Ductal Carcinoma of the Breast. United States and Canadian Academy of Pathology, Annual Meeting Boston, MA, 2009.
46. Maru DM, Singh RR, Hannah C, Albarracin CT, Romans A, Li YX, Abrahams R, Yao R, Luthra MG, Swisher SG, Hofstetter WL,Rashid AR,Luthra R. microRNA-196A: A Potential Marker of Progression in Barrett's Esophagus-Dysplasia-Adenocarcinoma Sequence. United States and Canadian Academy of Pathology, 2009 Annual Meeting Boston, MA, 2009.
47. Lester TR, Arun BK,Barrera A Gutierrez , Huo L, Albarracin CT, Gilcrease MZ. Triple-Negative Phenotype and/or High Mitotic Rate May Improve. United States and Canadian Academy of Pathology, Annual Meeting Boston, MA, 2009.
48. Cao Y, Li Y, Edelweiss M, Arun B, Rosen D, Resetkova E, Wu Y, Liu J, Sahin A, Albarracin CT. Loss of Annexin A1 expression in breast cancer progression. Appl Immunohistochem Mol Morphol 16(6):530-4, 2008. PMID: 18776816.
49. Peintinger F, Hatzis C, Morkowski J, Hubbard R, Albarracin C, Qureshi G, Pusztai L, Symmans W. Inter-pathologist agreement of residual cancer burden (rcb) assessment in breast cancer after treatment with preoperative chemotherapy. 44th ASCO Annual Meeting Chicago. IL(May 20 suppl):abstr 576, 2008.
50. Arun B, Atchley D, Litton J, Pusztai L, Valero V, Hortobagyi GN, Albarracin CT. Response to neoadjuvant chemotherapy in BRCA1 and BRCA2 related breast cancers. 44th ASCO Annual Meeting Chicago. IL(May 20 suppl):abstr 618, 2008.
51. Tang F, Gilcrease MZ, Albarracin CT, Huo L, Middleton LP, Resetkova E, Wu Y. Invasive Solid Papillary Carcinoma of the breast: A Clinicopathologic Analysis of 52 Cases. United States and Canadian Academy of Pathology 2008 Annual Meeting Denver, CO:abstr 248, 2008.
52. Downs-Kelly E, Nayeemuddin KM, Albarracin C, Wu Y, Hunt KK, Gilcrease MZ. Matrix-Producing Carcinoma of the Breast: Clinicopathologic Features Associated with Locoregional Recurrence and Survival. United States and Canadian Academy of Pathology 2008 Annual Meeting Denver, CO:abstr 120, 2008.
53. Nguyen CV, Albarracin C, Whitman GJ, Sneige N. Atypical Ductal Hyperplasia in Directional Vacuum-Assisted Biopsy of Breast Microcalcifications: Considerations for surgical excision. United States and Canadian Academy of Pathology 2008 Annual Meeting Denver, CO, 2008.
54. Li Y, Hu Y, Liu J, Albarracin CT. Inhibitory role of annexin A1 in breast cancer cell proliferation and tumor growth. American Association of Cancer Research, Annual Meeting San Diego, CA, 2008.
55. Duan X, Qu Z, Albarracin CT, Malpica A, Deavers M. Primary Leiomyosarcoma of Vagina: a Clinicopathologic Study. United States and Canadian Academy of Pathology Annual Meeting San Diego, CA, 2007.
56. Khalifeh I, Albarracin C, Wu Y, Sneige N. Histopathologic, biologic/molecular features of microglandular adenosis with transition into in-situ and invasive carcinoma. United States and Canadian Academy of Pathology Annual Meeting San Diego, CA, 2007.
57. Albarracin CT, Resetkova E, Wang H, Anderson P, Correa AM, Hofstetter WL, Swisher SG, Ajani JA, Tashid A, Hamilton SR, Wu TT. Expression of Annexin A1 in esophageal and esoghagogastric junction adenocarcinomas: association with poor outcome. United States and Canadian Academy of Pathology Atlanta, GA, 2006.
58. Guray M, Sun M, Albarracin CT, Edelweiss M, Johnson MM, Esteva FJ, Yu W, Sahin AA. Significant loss of PTEN protein expression in lymph node metastases of primary breast cancer: an immunohistochemical study using tissue microarray. United States and Canadian Academy of Pathology, Annual Meeting Atlanta, GA, 2006.
59. Shehu AK, Risk M, Jifang M, Albarracin CT, Gibori G. Mechanism of regulation of PRAP/17-beta hydroxysteroid dehydrogenase type 7 gene by estradiol. Annual Meeting of Endocrine Society Boston, MA, 2006.
60. Gullett AE, Fuller GN, Wu Y, Bruner JM, Albarracin CT. Increased annesin A1 expression in high-grade diffuse gliomas: a potential prognostic marker. United States and Canadian Academy of Pathology Annual Meeting Atlanta, GA, 2006.
61. Albarracin CT, Siguauke E, Yang W, Resetkova E, Selinko V, Whitman G, Sneige N. Columnar cell lesions with atypia: to excise or not to excise. San Antonio Breast Cancer Symposium San Antonio, TX, 2006.
62. Bicquart C, Kawase K, Garcia MK P, Rosen D, Symmans W F, Lui J, Albarracin CT. Evaluation of Epidermal Growth Factor Receptor (EGFR) and Estrogen Receptor (ER) in primary breast cancer and lymph node metastases using tissue. United States and Canadian Academy of Pathology San Antonio, Texas, 2005.
63. Kawase K, Hu Y X, Liu J, Albarracin CT. Potential role of Annexin A1 (ANXA1) as a growth inhibitor in breast cancer cell lines. American Association for Cancer Research Anaheim, CA, 2005.
64. Garcia MK P, Arun B, Albarracin CT, Sneige N. Estrogen receptor (ER) in breast fine needle aspirates (FNA) of women at increased risk for breast carcinoma. American Association for Cancer Research Anaheim, CA, 2005.
65. Cai Q, Albarracin C, Rosen DG, Zhong R, Zheng W, Broaddus R, Luthra R, Liu J. Microsatellite instability and alteration of expression of hMLH1 and hMSH2 in ovarian clear cell carcinoma. International Academy of Pathologists Vancouver, British Columbia, 2004.
66. Symmans WF, Fiteman DJ, Pusztai L, Stec J, Clark E, Dunmire V, Sneige N, Albarracin C, Rajan R, Linette G, Ross JS, Zhang W, Hortogabyi GN, Ayers M. Expression of the PI Subunit of γ-Aminobutyric acid type A receptor (GABA) is increased in breast cancers with combined estrogen receptor (ER) negative and Her-2/neu negative phenotype. International Academy of Pathologists Vancouver, British Columbia, 2004.
67. Resetkova E, Albarracin C, Sneige N. Collagenous spherulosis of the breast: morphologic study of 36 cases. International Academy of Pathologists Vancouver, British Columbia, 2004.
68. Gokhale S, Sneige N, Diaz LK, Rosen D, Resetkova E, Sahin A, Albarracin CT. Assessment of two automated systems of imaging technology in evaluation of estrogen receptor status in invasive carcinoma of breast. International Academy of Pathologists Vancouver, British Columbia, 2004.
69. Gokhale S, Albarracin C, Arun B, Middleton L, Sahin A. Immunohistochemical expression of prostate specific antigen in normal breast tissue and breast neoplasms. International Academy of Pathologists Washington D.C, 2003.
70. Albarracin CT, Arun B, Sahin A. Cell-specific dysregulation of annexin I in breast cancer. International Academy of Pathologists Washington D.C, 2003.
71. Albarracin CT, Gibori G, Rosen D, Cai K, Liu J. Prognostic significance and histotype-specific expression of annexin I in human ovarian cancers. International Academy of Pathologists Washington D.C, 2003.
72. Albarracin C, Silva E, Malpica A, Luthra R, Ku S, Yee S, Lui J. Microsatellite instability in ovarian endometrioid carcinoma: Identification of frameshift mutations in DNA mismatch repair genes, hMSH3 and hMSH6. International Academy of Pathologists Chicago, IL, 2002.
73. Albarracin CT, Ma J, Liu J. Loss of p27 expression predicts tumor progression in ovarian endometrioid carcinoma. International Academy of Pathologists Chicago, IL, 2002.
74. Albarracin CT, Luthra R, Thompson J, Kao S, Huang S, Liu JR. A novel tumor suppressor, is not a target of frameshift mutations in ovarian endometrioid carcinomas with microsatellite instability. International Academy of Pathologists Chicago, IL, 2002.
75. Albarracin CT, Montag AG, Recant W, Kuan SF. Mammary paget cells and toker cells express the same immunophenotype of mucin and cytokeratin genes. International Academy of Pathologists New Orleans, LA, 2000.
76. Albarracin CT, Rizzo P, Metkar C, Kuan SF, Jafri J, Carbone M, Montag AG. Identification of simian virus 40 DNA sequences in mixed mullerian tumors of the uterus. International Academy of Pathologists New Orleans, LA, 2000.
77. Albarracin CT, Jafri J, Hart J, Montag AG, Kuan SF. Differential expression of MUC2 and MUC5AC mucin gene products in primary and metastatic ovarian tumors. International Academy of Pathologists 644:111A, 1999.
78. Chin WW, Norwitz ER, Cardina GR, Jeong K-H, Albarracin CT, Kaiser UB. GnRH synthesis and regulation. Endocrinology, 1999.

Book Chapters

1. Sneige N, Albarracin C, Huo L. Immunological and Molecular Studies in Breast Tumors. In: Immunological and Molecular Diagnosis of Cancer, 2010.
2. Parmer TG, Khan I, Albarracin C, Zillberstein M, LeRoith D, Gibori G. Expression of IGF-I and IGF-I Receptor Gene in The Corpus Luteum. In: Ovarian Workshop, Regulatory Processes and Gene Expression in the Ovary. VIII. Springer-Verlag, NY, Inc: NY, 291-96, 1990.
3. Albarracin C, Gibori G. Prolactin Regulation and Developmental Expression of a 37,000 MW Protein in The Corpus Luteum. In: Ovarian Workshop, Regulatory Processes and Gene Expression in the Ovary. VIII. Springer-Verlag, NY, Inc: NY, 336-42, 1990.

Letters to the Editor

1. Albarracin C, Edgerton ME, Gilcrease MZ, Huo L, Krishnamurthy S, Middleton LP, Resetkova E, Sahin AA, Sneige N, Fraser WS, Wu Y. Is it too soon to start reporting HER2 genetic heterogeneity?. Arch Pathol Lab Med 134: 162-3; author reply 163, 2010.
2. Albarracin CT, Nguyen C, Whitman G, Yang W, Sneige N. Identifying Low Risk Patients with ADH Diagnosed on Core Needle Biopsy. Radiology, 2010.